Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

126.19USD
24 Apr 2018
Change (% chg)

$-0.64 (-0.50%)
Prev Close
$126.83
Open
$126.94
Day's High
$127.46
Day's Low
$125.33
Volume
1,961,790
Avg. Vol
2,435,947
52-wk High
$148.32
52-wk Low
$122.15

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.53 30.95 32.74
EPS (TTM): 5.91 -- --
ROI: 13.49 14.84 14.38
ROE: 22.63 16.34 16.07

Kentucky accuses J&J of contributing to opioid epidemic

Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

18 Apr 2018

UPDATE 1-Kentucky accuses J&J of contributing to opioid epidemic

April 18 Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

18 Apr 2018

Kentucky accuses J&J of contributing to opioid epidemic

April 18 Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

18 Apr 2018

Exclusive: Imerys selling one billion euro tiles business, buyout funds bidding - sources

LONDON/FRANKFURT France's Imerys is selling its roof tiles business as it streamlines its portfolio, people close to the matter said, expecting the asset to be valued at around 1 billion euros ($1.2 billion), with private equity most likely to clinch the deal.

18 Apr 2018

CORRECTED-UPDATE 1-J&J quarterly profit beats on demand for cancer drugs

April 17 Johnson & Johnson reported a better-than-expected first-quarter profit on Tuesday and raised its full-year sales forecast, helped by growing demand for its cancer drugs.

17 Apr 2018

BRIEF-J&J Says Estimates About 70% Of Cumulative Pre-Tax Costs Relating To Global Supply Chain Actions Will Result In Cash Outlays

* J&J SAYS ESTIMATES THAT ABOUT 70% OF CUMULATIVE PRE-TAX COSTS RELATING TO GLOBAL SUPPLY CHAIN ACTIONS WILL RESULT IN CASH OUTLAYS - SEC FILING Source text: (https://bit.ly/2H9L0dv) Further company coverage:

17 Apr 2018

BRIEF-J&J Posts Q1 Adj Non-Gaap EPS $2.06

* Q1 EARNINGS PER SHARE VIEW $2.02 -- THOMSON REUTERS I/B/E/S

17 Apr 2018

Johnson & Johnson quarterly sales rise 12.6 pct

April 17 Healthcare conglomerate Johnson & Johnson on Tuesday posted a 12.6 percent rise in quarterly sales, helped by strong demand for its cancer drugs.

17 Apr 2018

J&J Baby Powder litigation takes new focus with asbestos claims

NEW YORK A $117 million verdict against Johnson & Johnson and a supplier in favor of a man who said his asbestos-related cancer was caused by long-term use of J&J's Baby Powder could open a new front for thousands of cases claiming the widely-used product caused cancer, legal experts and plaintiffs lawyers said.

16 Apr 2018

J&J, Imerys unit must pay $117 million in New Jersey asbestos cancer case

NEW YORK Johnson & Johnson and Imerys Talc America, a unit of Imerys SA , must pay $117 million in damages in a case involving a man who said he developed cancer due to his exposure to asbestos in talc-based products, a New Jersey state court jury said on Wednesday.

12 Apr 2018

Earnings vs. Estimates